EGFR and cancer: These compiled approaches have shifted conventional cancer care and drastically improved precision oncology.19 As a result, the National Comprehensive Cancer Network issues guidelines for mutation testing in recurrent oncogenes EGFR, ALK, ROS1, BRAF, and NTRK intending to identify rare mutations for which effective drugs may be available.